Bank of America Adjusts Hims and Hers Stock Price Target
Bank of America raised its price target on Hims & Hers (HIMS) to $32 from $30, citing the company's ability to prescribe Eli Lilly's weight-loss medications through the LillyDirect pharmacy system. This marks the second price target increase by the firm this month, though the catalyst differs from the previous one. The move comes amid heightened analyst activity and market interest in the digital health sector.
Topics: analyst upgrade digital health pharmaceutical partnerships stock price target